CN111440872A - Kit for detecting methylation of gastric cancer related genes and application of kit - Google Patents

Kit for detecting methylation of gastric cancer related genes and application of kit Download PDF

Info

Publication number
CN111440872A
CN111440872A CN202010377370.2A CN202010377370A CN111440872A CN 111440872 A CN111440872 A CN 111440872A CN 202010377370 A CN202010377370 A CN 202010377370A CN 111440872 A CN111440872 A CN 111440872A
Authority
CN
China
Prior art keywords
sdc2
gene
kit
tert
methylation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010377370.2A
Other languages
Chinese (zh)
Inventor
王军一
肖雯
刘杰
尚慧捷
王核
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hangzhou Heyi Gene Technology Co ltd
Original Assignee
Hangzhou Heyi Gene Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Heyi Gene Technology Co ltd filed Critical Hangzhou Heyi Gene Technology Co ltd
Priority to CN202010377370.2A priority Critical patent/CN111440872A/en
Publication of CN111440872A publication Critical patent/CN111440872A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to a kit for detecting methylation of gastric cancer related genes, which is simple and convenient to operate, noninvasive, and higher in sensitivity and specificity, and application thereof, wherein the kit comprises a nucleic acid separation and purification reagent, a DNA sulfite conversion reagent, SDC2 and a TERT gene methylation detection reagent; wherein the nucleic acid separation and purification reagent is used for separating and purifying human source DNA in the excrement sample; DNA sulfite conversion reagents were used to sulfite convert purified portions of human DNA, SDC2 and TERT gene methylation detection reagents were used for subsequent detection of SDC2 and TERT gene methylation levels. The invention has the advantages of convenient sampling, no wound, convenience, no environmental interference, capability of realizing full coverage of stomach pathological changes, and suitability for popularization in popular physical examination and people needing to screen abnormal stomach diseases.

Description

Kit for detecting methylation of gastric cancer related genes and application of kit
Technical Field
The invention relates to the technical field of molecular biology, in particular to a kit for detecting methylation of gastric cancer related genes, which is simple and convenient to operate, has no wound and has higher sensitivity and specificity, and an application thereof.
Background Art Artificial sequence
Gastric cancer is one of common digestive tract tumors and seriously threatens the life and health of human beings. In recent decades, the incidence of gastric cancer generally decreases with the improvement of living conditions, the formation of good eating habits, the eradication of Helicobacter Pylori (HP), and other factors, but the incidence is high in the fourth place of male tumor and the mortality is the third place in the world.
The main stomach cancer screening methods at home and abroad are divided into two types: serological screening and endoscopic screening. Serological screening markers include pepsinogen, gastrin, Hp infection, MG7 antigen, carbohydrate antigen, and the like, and endoscopic screening includes electronic gastroscope, magnetic control capsule gastroscope, and the like. The serological screening method is simple and convenient to operate, has certain sensitivity and specificity, but is not high enough and not accurate enough; endoscopy and pathological analysis are the gold standards for diagnosing gastric cancer, but rely on equipment and endoscopic physician resources, have certain pain, and are not high in patient compliance, so that large-scale screening cannot be carried out.
TERT promoter methylation is a potential marker for gastrointestinal cancer. According to literature reports, in a clinical test consisting of stool samples of 69 gastrointestinal cancer patients (35 gastric cancers and 34 intestinal cancers) and 62 healthy adults, the sensitivity and specificity of combined detection of gastrointestinal cancer at two methylation sites on a TERT gene promoter are 52.2% and 90%, respectively; the sensitivity and specificity for detecting gastric cancer are 54.3% and 90%, respectively, and the sensitivity and specificity for detecting intestinal cancer are 50% and 90%, respectively.
In addition, SDC2 gene methylation is also an important marker for gut tumors. According to literature reports, SDC2 is a potential marker of colorectal cancer with significantly higher methylation levels in colorectal cancer tissues than in normal tissues. Through clinical verification, the sensitivity of detecting colorectal cancer by using the methylation of the faecal SDC2 gene is 81.1% (159/196), the sensitivity of detecting adenoma is 58.2% (71/122), and the total specificity is 93.3% (167/179). Meanwhile, the methylation detection of the SDC2 in the feces is also approved by NMPA and can be used for the auxiliary diagnosis of colorectal cancer. In addition to colorectal cancer, the methylation level of SDC2 gene was also significantly higher in gastric cancer tissues than in normal tissues. The methylation level of the SDC2 gene promoter in gastric cancer tissues is obviously higher than that of normal tissues through searching a MethHC database, and the gene is a potential marker for screening gastric cancer.
In addition, the methylation of RASSF2 and SFRP2 gene promoters can be used for detecting gastrointestinal tumors. In a clinical trial consisting of stool samples of 21 gastric cancers, 152 intestinal cancers, 10 patients with non-tumor or inflammatory lesions and 113 normal controls, the methylation of the RASSF2 and SFRP2 gene promoters combined detected gastric cancer at 57.1% sensitivity, colorectal cancer at 75% sensitivity, and advanced colorectal adenoma at 44.4% sensitivity, with specificity around 90%.
In conclusion, the purpose of screening gastrointestinal tumors can be realized by detecting gene methylation markers in the DNA of the excrement.
Disclosure of Invention
The invention aims to solve the problems of the existing gastric cancer screening method and provides a kit for detecting gastric cancer and a using method thereof, namely, the gastric cancer is detected by collecting excrement samples of detected persons and detecting the levels of two gene methylation markers in a combined manner, the operation is simple and convenient, the detection is noninvasive, and the kit has higher sensitivity and specificity.
In order to achieve the purpose, the invention adopts the following technical scheme:
a kit for detecting methylation of a gastric cancer-associated gene, the kit comprising a nucleic acid isolation and purification reagent, a DNA sulfite conversion reagent, SDC2 and a TERT gene methylation detection reagent; wherein the nucleic acid separation and purification reagent is used for separating and purifying human source DNA in the excrement sample; DNA sulfite conversion reagents were used to perform sulfite conversion of purified portions of human DNA, SDC2 and TERT gene methylation detection reagents were used for subsequent detection of SDC2 and TERT gene methylation levels.
Preferably, the SDC2 and TERT gene methylation detection reagents comprise a premixed reagent, water, and primers and probes for two target genes and an internal reference gene.
Preferably, the two target genes are SDC2 and TERT, respectively, and the reference gene is GAPDH.
Preferably, the sequences of the target gene and the reference gene are respectively:
SDC2 forward primer: aataagtgagagggcgtcgc
SDC2 reverse primer: aaactcgaactcgaaactcg
SDC2 probe: aacgctcgcttcctcctcctacgc
TERT forward primer: gtttagattttcgggttcgttcg
TERT reverse primer: gtctatacccgcgaatccactaa
TERT probe: cgacctaaccccgacaacgcaa
GAPDH forward primer: ggaggtaattaggatggtgtggtt
GAPDH reverse primer: catcrccccctaattttaaaaa
GAPDH probe: tgggtatatggtaattttgt are provided.
The application of the kit for detecting the methylation of the gastric cancer related gene comprises the following steps:
1) collecting and processing a fecal sample, and collecting a sample for gene detection;
2) extracting DNA of the fecal sample, and separating nucleic acid by a magnetic bead method by adopting a nucleic acid separation and purification reagent;
3) transforming the separated and purified nucleic acid by using bisulfite, and detecting the methylation level of the SDC2 and TERT gene in the sample by using a fluorescence quantitative PCR method;
4) and (6) analyzing results.
Preferably, the result analysis is to set a fluorescence threshold according to the amplification curve after the PCR reaction is finished, so as to obtain Ct values of different channels.
Preferably, the Ct value of the reference gene is less than or equal to 35, which indicates that the detection is qualified; the Ct value of the target gene SDC2 is positive when less than 40, and is negative when no Ct value is more than 40; the target gene TERT is positive if Ct value is less than 35 and is negative if Ct value is more than or equal to 35.
Preferably, if any target gene methylation marker is detected to be positive, the final result is judged to be positive, and a gastroscopy is required to be carried out subsequently to confirm the diagnosis.
Preferably, the SDC2 and TERT gene methylation detection reagents comprise a premixed reagent, water, and primers and probes for two target genes and an internal reference gene.
Preferably, the sequences of the target gene and the reference gene are respectively:
SDC2 forward primer: AATAAGTGAGAGGGCGTCGC
SDC2 reverse primer: AAACTCGAACTCGAAACTCG
SDC2 probe: AACGCTCGCTTCCTCCTCCTACGC
TERT forward primer: GTTTAGATTTTCGGGTTCGTTCG
TERT reverse primer: GTCTATACCCGCGAATCCACTAA
TERT probe: CGACCTAACCCCGACAACGCAA
GAPDH forward primer: GGAGGTAATTAGGATGGTGTGGTT
GAPDH reverse primer: CATCRCCCCACTTAATTTTAAAAA
GAPDH probe: TGGGTATATGGTAATTTTGT are provided.
The invention has the beneficial effects that:
1. the sensitivity of the kit for detecting the gastric cancer can reach about 80%, the specificity exceeds 80%, and the kit can realize high-sensitivity and high-specificity detection of the gastric cancer;
2. the invention has convenient sampling, no wound, convenience and no environmental interference, can realize the full coverage of stomach pathological changes, and is more suitable for popularization in the popular physical examination and the population needing to screen abnormal stomach diseases.
The kit for detecting gastric cancer related gene methylation and the use method thereof can be used for noninvasive and convenient screening of gastric cancer, have high specificity and high accuracy, and can be clinically used as an auxiliary detection index for early prevention and screening of tumorigenesis.
Drawings
FIG. 1 is a flow chart of the detection of the kit of the present invention;
FIG. 2 is a graph showing a positive result of the gene methylation detection;
FIG. 3 is a graph showing the negative results of the gene methylation assay.
Detailed Description
Embodiments of the invention are described in further detail below with reference to the accompanying drawings: materials and reagents required in the examples of the present invention are commercially available unless otherwise specified.
Example 1
1. Collection of fecal samples
Immediately collecting 2-5g of excrement sample after human excreting excrement, putting the excrement sample into a collecting tube, wherein 10-15m L excrement storage liquid is filled in the collecting tube, and shaking up the collecting tube to fully and uniformly mix the excrement sample and the excrement storage liquid;
the feces retaining liquid comprises the following components: 0.3-0.6M EDTA, 3-6M NaCl, 0.3-1.5M Tris;
2. fecal DNA extraction
The fecal DNA extraction is divided into the following steps: (1) precipitating the cells; (2) lysing the cells to release the DNA; (3) precipitating impurities; (4) removing impurities and purifying DNA; (5) binding magnetic beads with DNA; (6) magnetic bead washing and DNA elution.
For specific steps, please refer to the patent "a human fecal DNA extraction method" published in 2018, 11/23, application No.: CN201810812474.4, which will not be described herein.
3. DNA bisulfite conversion
The method is characterized in that after a thermal denaturation method is adopted for 10-20 minutes at 95 ℃, the DNA is immediately frozen for 5-10 minutes to prevent renaturation, then the DNA is converted for 45-60 minutes at 75 ℃, and the converted DNA is purified by a magnetic bead method and a binding solution containing PEG6000/8000, so that the methylated DNA with high conversion rate and high quality can be obtained, the standardization and full-automatic operation of methylation detection is facilitated, and the method is used for the methylation level analysis of genes in human DNA in subsequent fecal samples.
For the specific steps, please refer to the patent "a human feces total DNA sulfite transformation and recovery purification" published by the applicant at 2018, 12, month and 7, with the application numbers: CN201810814365.6, which will not be described herein.
4. Fluorescent quantitative PCR
SDC2 and TERT gene methylation levels are detected by a fluorescent quantitative PCR method, detection is carried out by an ABI7500 device, the total reaction system is 35ul, and 17.5ul of PCR premixed reagent, 2.5ul of reaction liquid and 15ul of DNA after bisulfite conversion are included. The PCR premixed reagent is a commercial quantitative PCR reaction mixed reagent, the reaction solution consists of a probe (100uM, 0.105ul) (synthesized by professional probe synthesis company), a primer (positive and negative primers, 100uM, 0.315ul 2) (synthesized by professional primer synthesis company), and water (1.765ul), and each reaction solution of SDC2, TERT and a reference Gene (GAPDH).
The reaction parameters are shown in table 1:
table 1: PCR reaction parameters
Figure BDA0002480662940000051
And after the reaction is finished, setting a proper fluorescence threshold value according to the amplification curve to obtain Ct values of different channels.
5. Analysis of detection results
(1) Reagent validity determination
Weak positive control: the Ct value of the VIC channel of the reference gene is less than or equal to 35; FAM channel Ct values for target genes (SDC2 and TERT) were less than 40 and 35, respectively; the amplification curve has obvious exponential growth period;
blank control: the FAM channels of the internal reference gene VIC channel and the target genes (SDC2 and TERT) have no amplification curve or the amplification curve is a straight line or a slightly oblique line and has no obvious exponential growth period.
(2) Sample validity determination
The Ct value of the internal reference gene in the sample detection result is less than or equal to 35, and the amplification curve has an obvious exponential amplification period.
(3) Determination of results of single-Gene methylation detection
Table 2: determination of results
Figure BDA0002480662940000052
6. Determination of results
And (3) the Ct value of the internal reference gene is less than or equal to 35, which indicates that the detection is qualified, and the result of the detected sample is comprehensively judged according to the detection levels of the methylation markers of the SDC2 gene and the TERT gene, namely the Ct value, so as to evaluate whether the detected person is a high-risk group with gastric cancer.
Specific judgment criteria are as follows:
if the detection result of any target gene methylation marker is positive, the final result is judged to be positive, the high risk of gastric cancer is met, and follow-up gastroscopy is recommended.
Limitations of the detection method:
a. the results of the sample testing are related to the quality of the sample collection, handling and storage, where any error will result in inaccurate test results. If the quality of the DNA is not well controlled during sample processing, false negative results may occur.
b. The result is only for reference and can not be directly used as evidence for determining gastric cancer, and patients with positive detection result need to be subjected to gastroscopy for determining the gastric cancer.
Example 2
Clinical sample test results
A total of 27 gastric cancer samples and 54 non-gastric cancer samples were collected. Then two genes in the fecal sample are respectively detected
(SDC2 and TERT) methylation levels, and then all clinical samples were classified by the positive decision criteria in example one, the sensitivity of the final model to differentiate gastric cancer (high risk) samples reached 81.5% (22/27) and the specificity reached 85.2% (46/54).
Table 3: example II partial sample pathological information and model determination results
Sample numbering Type of pathology GAPDH Methylation of SDC2 TERT methylation The result of the judgment
T1 Stomach cancer 28.2 33.9 33.7 Positive/high risk
T2 Stomach cancer 32.3 38.9 36.6 Positive/high risk
T3 Stomach cancer 32.9 41.2 33.1 Positive/high risk
T4 Stomach cancer 33.5 38.3 35.4 Positive/high risk
T5 Stomach cancer 33.4 40.5 38.4 Negative/low risk
N1 Non-gastric cancer 31.6 42.0 38.9 Negative/low risk
N2 Non-gastric cancer 32.9 41.1 40.3 Negative/low risk
N3 Non-gastric cancer 33.2 40.7 37.3 Negative/low risk
N4 Non-gastric cancer 34.6 41.8 39.2 Negative/low risk
N5 Non-gastric cancer 33.3 38.5 41.5 Positive/high risk
Patients who have a positive test result need to be gastroscopically examined to confirm the diagnosis.
The sensitivity for detecting the gastric cancer can reach about 80 percent, the specificity exceeds 80 percent, and the high-sensitivity and high-specificity detection of the gastric cancer can be realized.
The invention provides a kit for detecting gastric cancer, which comprises a nucleic acid separation and purification reagent, a DNA sulfite conversion reagent, SDC2 and a TERT gene methylation detection reagent; wherein the nucleic acid separation and purification reagent is used for separating and purifying human source DNA in the excrement sample; DNA sulfite conversion reagents were used to sulfite convert purified portions of human DNA for subsequent detection of SDC2 and TERT gene methylation levels.
The invention has the advantages of convenient sampling, no wound, convenience, no environmental interference, capability of realizing full coverage of stomach pathological changes, and suitability for popularization in popular physical examination and people needing to screen abnormal stomach diseases.
The kit for detecting gastric cancer related gene methylation and the use method thereof can be used for noninvasive and convenient screening of gastric cancer, have high specificity and high accuracy, and can be clinically used as an auxiliary detection index for early prevention and screening of tumorigenesis.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that various changes may be made and equivalents may be substituted for elements thereof; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions.
Sequence listing
<110> Hangzhou and Yi Gene science and technology Co Ltd
<120> kit for detecting methylation of gastric cancer related genes and application thereof
<141>2020-05-07
<160>9
<170>SIPOSequenceListing 1.0
<210>1
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>1
aataagtgag agggcgtcgc 20
<210>2
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
aaactcgaac tcgaaactcg 20
<210>3
<211>24
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
aacgctcgct tcctcctcct acgc 24
<210>4
<211>23
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
gtttagattt tcgggttcgt tcg 23
<210>5
<211>23
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
gtctataccc gcgaatccac taa23
<210>6
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
cgacctaacc ccgacaacgc aa 22
<210>7
<211>24
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
ggaggtaatt aggatggtgt ggtt 24
<210>8
<211>24
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>8
catcrcccca cttaatttta aaaa 24
<210>9
<211>20
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>9
tgggtatatg gtaattttgt 20

Claims (10)

1. A kit for detecting methylation of a gastric cancer-associated gene, the kit comprising a nucleic acid isolation and purification reagent, a DNA sulfite conversion reagent, SDC2 and a TERT gene methylation detection reagent; wherein the nucleic acid separation and purification reagent is used for separating and purifying human source DNA in the excrement sample; DNA sulfite conversion reagents are used to sulfite convert purified portions of human DNA characterized by SDC2 and TERT gene methylation detection reagents for subsequent detection of SDC2 and TERT gene methylation levels.
2. The kit for detecting methylation of gastric cancer-associated genes according to claim 1, wherein the SDC2 and TERT gene methylation detection reagents comprise premixed reagents, water, and primers and probes for two target genes and an internal reference gene.
3. The kit for detecting methylation of gastric cancer-associated genes according to claim 2, wherein the two target genes are SDC2 and TERT, and the reference gene is GAPDH.
4. The kit for detecting methylation of gastric cancer-associated genes according to claim 2 or 3, wherein the sequences of the target gene and the reference gene are respectively:
SDC2 forward primer: AATAAGTGAGAGGGCGTCGC
SDC2 reverse primer: AAACTCGAACTCGAAACTCG
SDC2 probe: AACGCTCGCTTCCTCCTCCTACGC
TERT forward primer: GTTTAGATTTTCGGGTTCGTTCG
TERT reverse primer: GTCTATACCCGCGAATCCACTAA
TERT probe: CGACCTAACCCCGACAACGCAA
GAPDH forward primer: GGAGGTAATTAGGATGGTGTGGTT
GAPDH reverse primer: CATCRCCCCACTTAATTTTAAAAA
GAPDH probe: TGGGTATATGGTAATTTTGT are provided.
5. Use of the kit for detecting methylation of gastric cancer-associated genes according to any one of claim 1, wherein the use method comprises the following steps:
1) collecting and processing a fecal sample, and collecting a sample for gene detection;
2) extracting DNA of the fecal sample, and separating nucleic acid by a magnetic bead method by adopting a nucleic acid separation and purification reagent;
3) transforming the separated and purified nucleic acid by using bisulfite, and detecting the methylation level of the SDC2 and TERT gene in the sample by using a fluorescence quantitative PCR method;
4) and (6) analyzing results.
6. The application of the kit for detecting methylation of gastric cancer-related genes according to claim 5, wherein the result analysis is to set a fluorescence threshold according to an amplification curve after the PCR reaction is finished, so as to obtain Ct values of different channels.
7. The application of the kit for detecting methylation of gastric cancer-related genes according to claim 6, wherein the Ct value of the reference gene is less than or equal to 35, which indicates that the detection is qualified; the Ct value of the target gene SDC2 is positive when less than 40, and is negative when no Ct value is more than 40; the target gene TERT is positive if Ct value is less than 35 and is negative if Ct value is more than or equal to 35.
8. The use of the kit according to claim 7, wherein the detection result of any one target gene methylation marker is positive, and the final result is determined to be positive, and a gastroscopy is required for confirmation.
9. The application of the kit for detecting the methylation of the gastric cancer-associated genes according to claim 5, wherein the SDC2 and the TERT gene methylation detection reagent comprise a premixed reagent, water, and primers and probes of two target genes and an internal reference gene.
10. The use of the kit according to claim 9, wherein the sequences of the target gene and the reference gene are respectively:
SDC2 forward primer: AATAAGTGAGAGGGCGTCGC
SDC2 reverse primer: AAACTCGAACTCGAAACTCG
SDC2 probe: AACGCTCGCTTCCTCCTCCTACGC
TERT forward primer: GTTTAGATTTTCGGGTTCGTTCG
TERT reverse primer: GTCTATACCCGCGAATCCACTAA
TERT probe: CGACCTAACCCCGACAACGCAA
GAPDH forward primer: GGAGGTAATTAGGATGGTGTGGTT
GAPDH reverse primer: CATCRCCCCACTTAATTTTAAAAA
GAPDH probe: TGGGTATATGGTAATTTTGT are provided.
CN202010377370.2A 2020-05-07 2020-05-07 Kit for detecting methylation of gastric cancer related genes and application of kit Pending CN111440872A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010377370.2A CN111440872A (en) 2020-05-07 2020-05-07 Kit for detecting methylation of gastric cancer related genes and application of kit

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010377370.2A CN111440872A (en) 2020-05-07 2020-05-07 Kit for detecting methylation of gastric cancer related genes and application of kit

Publications (1)

Publication Number Publication Date
CN111440872A true CN111440872A (en) 2020-07-24

Family

ID=71652018

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010377370.2A Pending CN111440872A (en) 2020-05-07 2020-05-07 Kit for detecting methylation of gastric cancer related genes and application of kit

Country Status (1)

Country Link
CN (1) CN111440872A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023071889A1 (en) * 2021-10-25 2023-05-04 广州市基准医疗有限责任公司 Methylation biomarker related to detection of gastric cancer lymph node metastasis, or combination thereof and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216660A1 (en) * 2006-12-19 2010-08-26 Yuri Nikolsky Novel methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
CN102858985A (en) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 Method for genome editing
CN106232833A (en) * 2014-01-30 2016-12-14 加利福尼亚大学董事会 The haplotyping that methylates (MONOD) for non-invasive diagnostic
CN106399570A (en) * 2016-11-30 2017-02-15 杭州诺辉健康科技有限公司 Kit for early stage colorectal cancer auxiliary diagnosis and use method and detection system thereof
CN108977544A (en) * 2018-08-06 2018-12-11 北京艾克伦医疗科技有限公司 For identifying kit and its application of gastric cancer and/or polyp of stomach
CN109097471A (en) * 2018-08-21 2018-12-28 杭州和壹基因科技有限公司 A kind of kit detected for colorectal cancer and precancerous lesion and its application method

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216660A1 (en) * 2006-12-19 2010-08-26 Yuri Nikolsky Novel methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
CN102858985A (en) * 2009-07-24 2013-01-02 西格马-奥尔德里奇有限责任公司 Method for genome editing
CN106232833A (en) * 2014-01-30 2016-12-14 加利福尼亚大学董事会 The haplotyping that methylates (MONOD) for non-invasive diagnostic
CN106399570A (en) * 2016-11-30 2017-02-15 杭州诺辉健康科技有限公司 Kit for early stage colorectal cancer auxiliary diagnosis and use method and detection system thereof
CN108977544A (en) * 2018-08-06 2018-12-11 北京艾克伦医疗科技有限公司 For identifying kit and its application of gastric cancer and/or polyp of stomach
CN109097471A (en) * 2018-08-21 2018-12-28 杭州和壹基因科技有限公司 A kind of kit detected for colorectal cancer and precancerous lesion and its application method

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GYEONG HOON KANG等: "DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis" *
LI LIU等: "TERT Promoter Hypermethylation in Gastrointestinal Cancer: A Potential Stool Biomarker" *
YOON DAE HAN等: "Early detection of colorectal cancer based on presence of methylated syndecan-2(SDC2) in stool DNA" *
郭鹏: "粪便生物标志物检测在胃癌筛查中的应用探索" *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023071889A1 (en) * 2021-10-25 2023-05-04 广州市基准医疗有限责任公司 Methylation biomarker related to detection of gastric cancer lymph node metastasis, or combination thereof and use thereof

Similar Documents

Publication Publication Date Title
CN102311953B (en) Method and kit for diagnosing bladder cancer with urine
JP2019501651A (en) Tumor molecule detection / diagnostic reagents
WO2019233102A1 (en) Primer and probe set for diagnosis, detection, or screening of colorectal cancer
CN108866192A (en) Tumor marker STAMP-EP1 based on methylation modification
CN111778332A (en) Marker combination and kit for early diagnosis of adenoma and colorectal cancer
CN112646891B (en) Digestive tract tumor marker combination, detection kit and application thereof
CN107955832A (en) It is a set of while detect poor, deaf, phenylketonuria, the primer sets of hepatolenticular degeneration and method
CN112609015A (en) Microbial marker for predicting colorectal cancer risk and application thereof
CN108374047B (en) Kit for detecting bladder cancer based on high-throughput sequencing technology
CN116121380A (en) Primer probe combination for detecting bladder cancer related genes and detection method
CN113724862A (en) Colorectal cancer biomarker and screening method and application thereof
CN111500730A (en) Early diagnosis marker for colorectal cancer and precancerous lesion thereof and application thereof
CN113943799A (en) Composition for detecting bladder cancer, kit and application thereof
CN115287350A (en) Application of exosome miR-106b-3p, miR-10a-3p and the like in lung cancer diagnosis
CN108660209B (en) Product for early detection of colorectal cancer prepared based on BMP3 gene methylation
CN112708673B (en) Application of PRDM9 transposon fusion as congenital megacolon disease marker
CN111440872A (en) Kit for detecting methylation of gastric cancer related genes and application of kit
CN115961038B (en) Composition for detecting gastric cancer, kit and application thereof
CN114107498B (en) Colorectal cancer blood detection marker and application thereof
CN112852934B (en) Primer, reagent and kit for detecting gene methylation
CN111793688B (en) Primer probe group and kit for detecting digestive tract tumor markers and application of primer probe group and kit
CN114085905B (en) Composition for detecting colorectal cancer, kit and application thereof
CN108251532B (en) Fecal DNA colorectal tumor polygene prediction model based on NGS technology
CN108460247B (en) Method and system for determining colorectal tumor cells based on KRAS and NDRG4 genes
CN115747333B (en) Tumor marker detection kit, detection analysis system and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200724